Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
- Published In:
- Diabetes, obesity & metabolism, 15(8), 737-49 (2013)
- Database ID:
- RPEP-02298
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-02298APA
Wang, B; Zhong, J; Lin, H; Zhao, Z; Yan, Z; He, H; Ni, Y; Liu, D; Zhu, Z. (2013). Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.. Diabetes, obesity & metabolism, 15(8), 737-49. https://doi.org/10.1111/dom.12085
MLA
Wang, B, et al. "Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.." Diabetes, 2013. https://doi.org/10.1111/dom.12085
RethinkPeptides
RethinkPeptides Research Database. "Blood pressure-lowering effects of GLP-1 receptor agonists e..." RPEP-02298. Retrieved from https://rethinkpeptides.com/research/wang-2013-blood-pressurelowering-effects-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.